MedTrace Logo

Nebulized Dexmedetomidine Versus Neostigmine/Atropine in Postdural Puncture Headache

NCT04910477 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-08

No results posted yet for this study

Summary

In our study, we will compare a new route of nebulization for effectiveness between dexmedetomidine, neostigmine/atropine and saline placebo for females complained of postdural puncture headache (PDPH) after cesarean section.

Conditions

  • Postdural Puncture Headache

Interventions

DRUG

Dexmedetomidine

ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.

DRUG

Neostigmine/atropine

nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.

OTHER

Saline placebo

nebulization of saline placebo in 4 ml) twice daily for three days.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Omar Soliman · Omar makram

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2021-09-01
Completion
2021-09-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910477 on ClinicalTrials.gov